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Abstract: Bypassing agents are the mainstay of treatment for patients with hemophilia 
with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the 
management of bleeding episodes in this population, timely administration of bypassing agents 
continues to be hampered by a number of practical limitations, including the need for refrigerated 
storage of the agent and its reconstitution at room temperature prior to administration, among 
others. In this review, the importance of early treatment of bleeds and factors that influence this 
more timely therapeutic approach are highlighted, together with the advantages offered by the 
use of a new formulation of recombinant activated factor VII that permits improved storage and 
portability, potentially optimizing timely bypassing agent administration.
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Introduction
The development of neutralizing alloantibodies (“inhibitors”) to factor VIII or factor 
IX complicates treatment in 20% to 30% of patients with hemophilia A and 3% to 5% 
of patients with hemophilia B.1 These inhibitors (polyclonal immunoglobulin G 
  antibodies) also affect any residual endogenous factor that the patient may have and 
make administration of a replacement factor ineffective, secondary to its rapid clearance 
from the circulation.2,3 Treatment options, potential complications, and cost of treat-
ment are markedly different for hemophilia patients with inhibitors than for hemophilia 
patients without inhibitors.1 Since patients with inhibitors no longer achieve adequate 
hemostasis with factor VIII or factor IX infusions, alternative treatments are required 
to reduce/eradicate inhibitor titers (eg, immune tolerance induction therapy) or induce 
coagulation via another pathway in the clotting cascade (ie, bypass therapy).
In this paper, we discuss the importance of early treatment of acute bleeds in 
patients with inhibitors, which offers a significant therapeutic advantage for minimiz-
ing re-bleeds, improves patient quality of life, and reduces consumption of bypassing 
agent.4 Early treatment can best be achieved by timely administration of bypassing 
therapy, which is dependent upon drug-related factors or properties that can either 
inhibit or facilitate this therapeutic goal in patients with inhibitors. Addressing this 
key point, we also detail the attributes of a new room temperature stable recombinant 
activated factor VII (rFVIIa) formulation that improves portability and convenience 
of administration, thereby increasing the likelihood of early and successful treatment 
of acute bleeding episodes in this patient population.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Importance of early treatment  
of acute bleeding episodes  
in inhibitor patients
Available data suggest that early intervention improves treat-
ment efficacy.4,5 Review of data from clinical trials and from 
studies of the compassionate use of rFVIIa have demonstrated 
a clear relationship between early treatment and achievement 
of excellent or effective treatment response, with 92% of 
patients achieving this endpoint when rFVIIa was initiated 
within a mean of 1.2 hours of the onset of bleeding versus 
only 63.1% when rFVIIa was given within a mean of 5 days 
after bleeding onset.5 Similarly, data from a prospective, 
observational registry comprising 128 bleeding episodes in 
15 patients with inhibitors demonstrated numerically lower 
rebleeding rates among patients treated with rFVIIa within 
2 hours (5.2%) versus patients treated more than 2 hours after 
the first bleeding symptoms appeared (13.7%).4 By mini-
mizing the extent of bleeding in the joint, prompt treatment 
may also delay the development of hemophilic arthropathy.6 
The improved efficacy of early treatment may also result in 
reduced bypassing agent consumption by patients. In the 
study by Lusher, the mean number of doses was lower among 
patients treated within a mean time interval of 1.2 hours 
(2.3 doses) than among patients treated within a mean time 
interval of 5 days (13.6 doses).5
Despite these findings showing the significant therapeutic 
benefit of early treatment of acute bleeds, timely management 
is not common among hemophilic youths in the United States. 
In a survey of 100 hemophilia patients aged 13 to 21 years, 
only 31% of respondents reported the administration of self-
treatment within 1 hour of the onset of a bleeding episode.7 
One of the most common reasons cited for treatment delay 
was the failure to have clotting factor with them at the time 
of the bleeding episode (25% of respondents).7
Bypassing therapy for patients  
with inhibitors
Acute bleeding or perioperative  
bleeding management
Historically, porcine factor VIII (pFVIII) has been used as 
an alternative to human-derived concentrates in patients with 
an inhibitor to factor VIII.8 pFVIII has been observed to be 
80% to 90% effective in patients with factor VIII inhibitors 
due to the low cross-reactivity to pFVIII.9–11 Plasma-derived 
pFVIII is no longer available because of a contamination with 
parvovirus,12 but a recombinant pFVIII product is currently 
in clinical development.13 In patients with high-responding 
inhibitors (titer .5 BU), acute bleeding is typically treated 
with an agent that bypasses the factor VIII or IX coagulation 
pathway, either activated prothrombin complex concentrates 
(aPCCs) or rFVIIa.2 In the United States, the only licensed 
aPCC is the plasma-derived factor VIII inhibitor bypassing 
activity, anti-inhibitor coagulant complex (FEIBA; Baxter 
AG, Vienna, Austria). Plasma-derived-aPCC (pd-aPCC) 
contains factor VII in mainly the activated form, as well as 
factor II, factor IX and factor X, in mainly non-activated 
forms.14 The precise mechanism by which pd-aPCC facilitates 
hemostasis is unknown, but prothrombin (factor II) and 
factor Xa are the primary active components, with other 
components including factor VIIa.14,15 A recent systematic 
review of available randomized clinical trial data showed 
that the pd-aPCC efficacy rate for controlling acute bleeding 
ranged from 64% to 80% of patients using dosing regimens 
according to published guidelines and manufacturer recom-
mendations.16 Pd-aPCC is effective in controlling hemorrhage 
at a variety of anatomic sites including joint, muscle, 
mucocutaneous, and central nervous system (CNS) and 
perioperative bleeding,17–19 and can also be used effectively to 
achieve hemostasis in a home-treatment setting.14 Mild adverse 
events, such as chills, fever, nausea, and dizziness, occur in 
a small proportion of patients,20 and there is a small risk of 
anaphylactic reactions.21 Thrombotic and thromboembolic 
events (including disseminated intravascular coagulation 
[DIC], venous thrombosis, pulmonary embolism, myocar-
dial infarction, and stroke) have been reported following 
infusion of pd-aPCC.21 Most of the thromboembolic events 
occurred when pd-aPCC was administered at doses higher 
than 200 units/kg/day and in patients with other risk factors 
for thromboembolic events.14,21,22 Patients receiving more 
than 100 units/kg of body weight of the concentrate must 
be monitored for the development of DIC and/or symptoms 
of acute coronary ischemia.21 In addition, the infusion time 
for this agent   varies from about 30–45 minutes per infusion, 
to minimize side effects of rapid infusion. Since pd-aPCC 
is derived from human plasma, there is also the theoretical 
potential for human viral transmission, although no cases of 
hepatitis or human immunodeficiency virus infection have 
been directly linked to use of this agent.22,23 In addition, 
  pd-aPCC contains trace amounts of factor VIII that may 
induce an anamnestic rise in factor VIII antibody titers in up 
to 30% of patients.19,21 This rise in antibody titers does not 
interfere with the efficacy of pd-aPCC and is transient in the 
majority of patients.20 Despite these limitations, this product 
has been widely used for about 30 years and continues to be 
used in patients who may not respond to rFVIIa.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Recombinant factorVIIa is the other currently available 
bypassing agent that was approved by the US Food and 
Drug Administration (FDA) in 1999 for use in patients with 
inhibitors. In contrast to pd-aPCC, rFVIIa is a recombinant 
protein produced by genetically engineered mammalian cells 
(baby hamster kidney cell line)24 and has little to no risk of 
human viral transmission.25,26 Furthermore, because it does 
not contain any residual procoagulant factor VIII or factor IX 
activity, the risk of an anamnestic response is precluded, and 
this agent can be used for patients with inhibitors to factor 
VIII or factor IX.23 In clinical studies, rFVIIa has been shown 
to be effective in restoring hemostasis in hemophilia A and 
hemophilia B patients with inhibitors who were experienc-
ing joint, muscle, dental, and CNS bleeds, or who underwent 
major and minor surgeries.27–32 An estimate of rFVIIa efficacy 
for controlling bleeding derived from a recent systematic 
analysis of available randomized clinical trial data showed an 
effective treatment response rate of 81% to 91% in patients 
with inhibitors experiencing acute bleeds.16 The most com-
monly reported adverse events in clinical studies were mild 
and included fever, skin reactions, headache, hypertension, 
epistaxis, shortened prothrombin time, and reduced fibrino-
gen levels.20 The risk of thromboembolic events with rFVIIa 
is low and similar to that observed with pd-aPCC.2
Although both types of bypassing agents can be adminis-
tered at home, rFVIIa may be more suited to this use because 
it is a low-volume injection that can be administered rapidly. 
However, rFVIIa has to be administered frequently, every 2 
to 3 hours because of its shorter half-life, whereas the recom-
mended interval between doses of pd-aPCC is 6 to12 hours.21 
The FEIBA NovoSeven Comparative (FENOC) Study was 
a head-to-head comparison of efficacy between pd-aPCC 
and rFVIIa, and was conducted as a prospective, open-label, 
crossover, randomized equivalency-designed clinical trial in 
which a difference in response at  6 hours after treatment of no 
more than 15% was determined to be clinically equivalent.33 At 
6 hours in the FENOC Study, the confidence interval reported 
for each product only slightly exceeded the 15% boundary 
(-11.4% to 15.7%, P = 0.059). The investigators, however, 
noted that their study was not designed nor adequately pow-
ered to provide evidence of the superiority of either   product. 
They further suggested that an individualized approach to 
therapy should be used to optimize therapy, as there was 
evidence of substantial interpatient variability.33
Prophylaxis
Because of the clear benefit of preventing hemarthrosis 
for the preservation of joint integrity and maintenance of 
  mobility and function,34 prophylaxis with factor VIII or IX 
is used routinely in many developed countries. Similarly, 
prophylaxis with bypassing agents is also being consid-
ered in inhibitor patients to minimize or prevent bleeding 
  episodes. The prophylactic use of bypassing agents has been 
examined in a randomized clinical trial and several small 
series of patients with hemophilia A and inhibitors. In a 
recent trial, 22 patients with inhibitors to factor VIII were 
randomized to once-daily injections of rFVIIa 90 mcg/kg 
or 270 mcg/kg prophylaxis for 3 months.35 rFVIIa treatment 
reduced the number of bleeds (45%–59%; P , 0.0001 versus 
no prophylaxis) and reduced hospital admissions and work/
school absences. Effects on bleeding frequency were largely 
maintained throughout a 3-month post-prophylaxis evalu-
ation period. In many reports from case series,   pd-aPCC 
and rFVIIa appeared to be effective and well tolerated as 
prophylactic therapy, with a reduced incidence of bleed-
ing episodes, fewer workdays missed, improved quality 
of life, and less need for on-demand therapy, all variously 
reported.36–42 However, concerns have been raised about the 
risks (particularly of thromboembolism) with repeated and 
frequent use of pd-aPCC and the potential for anamnestic 
increases in antibody titers.43 Although the available data on 
prophylaxis are promising, much more research is required 
before the prophylactic use of bypassing agents becomes 
routine practice, in particular, in terms of defining the opti-
mal regimen to use in this setting, the long-term risks and 
benefits, and the cost-utility of this approach.
Limitations
The availability of bypass agents has greatly advanced the 
treatment of hemophilia in patients with inhibitors; however, 
a few product-related practical limitations remain. Neither 
  pd-aPCC nor the original formulation of rFVIIa are suffi-
ciently stable at room temperature to be stored or transported 
without refrigeration.21,44 Thus, availability of product when 
away from home is dependent on an individual’s willing-
ness to carry a cooler. Delays in treatment also arise from 
the need to restore these agents to room temperature prior 
to reconstitution.21,44
New advance in formulation:  
room temperature stable rFVIIa
A room temperature stable formulation of rFVIIa     
(rFVIIa-RT; NovoSeven® RT; Novo Nordisk A/S,   Bagsvaerd, 
  Denmark)44 was approved by the FDA in May 2008. Stud-
ies have shown that this product can be stored at tem-
peratures of 2°C to 25°C (36°F–77°F) for up to 2 years Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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prior to   reconstitution and for up to 3 hours following 
  reconstitution.45 In addition, the concentration of this 
formulation was changed to make dosing calculations easier, 
and the vials are color coded to decrease confusion between 
the different vial sizes.
Stability
The stability of rFVIIa-RT, both in lyophilized and reconsti-
tuted forms, has been tested in a range of potential storage 
conditions.45 As reported in the study by Nedergaard et al, 
the specific activity of FVIIa in a 5 mg dose of rFVIIa-RT 
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Figure 1 A) Specific activity of the room temperature stable formulation of activated recombinant factor VII (rFVIIa-RT) during long-term storage at 5°C/41°F, 25°C/77°F, 
and 30°C/86°F, and during long-term storage at 40°C/104°F for 6 months followed by an additional 12 months at 25°C/77°F. Data for the 1 mg, 2 mg, and 5 mg product 
sizes were equivalent. Results from the 5 mg size are presented. B) Specific activity of rFVIIa-RT during storage at extreme temperatures for 12 hours. The broken lines 
represent the allowable upper and lower limit for each test parameter at the end of the product’s shelf-life, as adopted by the European Medicines Agency and the US Food 
and Drug Administration.45 
This article was published in Clinical Therapeutics, Nedergaard et al.45 Copyright © 2008, elsevier.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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lyophilized product was maintained after 24 months of 
  storage at 5°C (41°F) and 25°C (77°F), after 12 months and 
18 months of storage at 30°C (86°F), and after 6 months at 
40°C (104°F) followed by an additional 12 months at 25°C 
(77°F)   (Figure 1A).45 Moreover, rFVIIa-RT continued to 
maintain activity and was generally stable after 12 hours 
of storage at extreme temperatures (50°C [122°F], 60°C 
[140°F], and 70°C [158°F]) (Figure 1B),45 such as those that 
might be encountered during routine transport by patients. 
Stability and specific activity were also maintained when the 
rFVIIa-RT formulation was stored in the refrigerator (5°C 
[41°F]) and then at high room temperature (30°C [86°F]) 
for alternating periods over 5 days. Stability was independent 
of vial size.45
After reconstitution with histidine diluents, the   rFVIIa-RT 
formulation retained its activity and stability when stored for 
6 hours at 25°C (77°F) and for 24 hours at 5°C (41°F).45 
Another study demonstrated that rFVIIa-RT remained 
physically and chemically stable at 25°C (77°F) for 6 hours 
after reconstitution with sterile water for injection, physi-
ologic saline, or histidine diluent (Table 1).46 In this study, 
rFVIIa-RT was also shown to be stable at 5°C (41°F) for up 
to 24 hours when reconstituted with inappropriate diluents 
(sterile water for injection or physiologic saline) or the 
recommended histidine diluent. This is of interest to note in 
urgent or critical situations where only sterile saline or water 
for injection may be available for reconstitution. rFVIIa-RT 
stability is also maintained with various “incorrect” volumes 
of diluent.46 Reconstitution in double or half of the histidine 
solvent does not adversely affect stability; however, there 
is still a potential for dosing errors because the target final 
dose cannot be achieved if the correct diluent volume is 
not used.46
Stability at room temperature for this product was 
achieved through the addition of 2 new excipients to the 
lyophilized powder – a stabilizer (sucrose) and an antioxidant 
(methionine) – and by the use of a diluent containing histidine 
10 mmol/L in sterile water. Histidine, a naturally occurring 
amino acid, is used as a buffering agent in other marketed 
factor replacement products and thus has a history of safe 
use in this patient population.45,46
vial sizes
To aid in dose calculations at home, the concentration of 
rFVIIa-RT was changed to 1 mg/mL, and rFVIIa-RT is available 
in single-use vials containing 1 mg, 2 mg, or 5 mg of rFVIIa-RT 
per vial. This is in contrast to the original rFVIIa preparation, 
which was available in 1.2 mg, 2.4 mg, and 4.8 mg vial sizes. 
Because it is 40% more concentrated than the original rFVIIa 
formulation, the RT formulation allows for a lower infusion 
volume, and thus faster infusion than the original product.47 
To make administration easier and avoid confusion, the vials 
of rFVIIa-RT and corresponding vials of premeasured diluent 
now have matching color-coded caps to aid in differentiating 
between vials and to avoid medication errors.
Pharmacokinetic and pharmacodynamic 
equivalence
Pharmacokinetic and pharmacodynamic equivalence of 
rFVIIa-RT with original rFVIIa was demonstrated in 
a randomized, double-blind, 2-way crossover study in 
healthy volunteers.48 Factor VII activity over time was 
nearly identical with the 2 formulations (Figure 2A),48 and 
the 90% confidence intervals for difference in the primary 
end point of area under the curve was 0.93, well within 
the 0.8 to 1.25 definition of bioequivalence. Coagulation 
Table 1 In vitro stability of rFVIIa-RT after reconstitution with correct volumes of inappropriate solvents (sterile water for injection 
or saline) and the appropriate histidine solvent46
Storage 
time (h)
Storage 
temperature (°C/°F )
Concentration 
(mg/mL)
Dimer/oligomer 
formation (%)
Polymer 
formationa (%)
Heavy chain 
degradation (%)
Oxidized 
forms (%)
pH
rFVIIa-RT 1 mg reconstituted with 1.15 mL recommended solvent (histidine)
0 – 0.97 1.4 ,0.3 8.5 1.2 6.1
6 25/77 0.99 1.3 ,0.3 8.6 1.2 6.1
rFVIIa-RT 1 mg reconstituted with 1.15 mL sterile water
0 25/77 0.96 1.5 ,0.3 8.8 1.2 6.0
6 25/77 0.95 1.3 ,0.3 8.7 1.2 6.0
rFVIIa-RT 1 mg reconstituted with 1.15 mL physiologic saline
0 25/77 0.97 1.5 ,0.3 8.7 1.2 6.0
6 25/77 0.98 1.5 ,0.3 8.6 1.2 6.0
Note: aThe limit of quantification of the analysis was 0.3%. This article was published in Clinical Therapeutics, Petersson et al.46 Copyright © 2008, elsevier.
Abbreviation: rFVIIa-RT, room temperature stable activated recombinant factor VII.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
280
Butros et al
Table 2 Pharmacokinetic parameters after administration of single 
90 μg/kg doses of original rFVIIa or rFVIIa-RT in a randomized 
crossover study48
Mean (SD) pharmacokinetic 
parameter
rFVIIa
Original 
(n = 22)
RT 
(n = 22)
AUC0-t, h/iU/mL 122.04 (18.03) 113.26 (17.36)a
Cmax, iU/mL 55.44 (7.89) 52.83 (7.31)
AUC0–30, h/iU/mL  122.05 (18.01) 113.26 (17.36)
t½, h 3.48 (0.27) 3.54 (0.28)
Mean residence time, h 2.97 (0.26) 3.05 (0.27)
CL, mL/h/kg 37.63 (5.99) 40.43 (6.23)
vc, mL/kg 82.68 (12.50) 86.36 (12.31)
vss, mL/kg 111.31 (17.52) 122.96 (20.42)
Notes: aP = 0.1076 for RT vs original formulation.
Copyright © 2007, John wiley and Sons. Reproduced with permission from Bysted 
et al.48
Abbreviations:  rFVIIa,  activated  recombinant  factor  VII;  rFVIIa-RT,  room 
temperature stable rFviia; SD, standard deviation; AUC, area under the curve; Cmax, 
maximal concentration; t½, half-life; CL, clearance; Vc, volume of distribution in the 
central compartment; vss, volume of distribution at steady state.
100
1 Predose 61 2
Time (h)
M
e
a
n
 
D
-
d
i
m
e
r
 
(
n
g
 
m
L
−
1
)
18 24
1 Predose 61 2
Time (h)
18 24
−6 06 12
Time (h)
18 24 30
150
200
250
300
350
400
450
500
rFVIIa-RT
rFVIIa
rFVIIa-RT
rFVIIa
rFVIIa-RT
rFVIIa
0.10
M
e
a
n
 
f
r
a
g
m
e
n
t
 
1
 
+
 
2
 
(
n
m
o
l
 
L
−
1
)
0.15
0.20
0.25
0.30
0.01
F
V
I
I
a
 
a
c
t
i
v
i
t
y
 
(
I
U
 
m
L
−
1
)
0.10
1.00
10.00
100.00 A
B
C
Figure 2 Comparison of the time course of effect of original activated recombinant 
factor VII (rFVIIa) and the room temperature stable formulation of rFVIIa (rFVIIa-RT) 
in  a  single-dose,  randomized,  crossover  study.48  A)  Mean  (SD)  plasma-activated 
rFVIIa activity (logarithmic scale); B) Mean prothrombin fragment F1+2 levels; C) Mean 
D-dimer levels.
Copyright © 2007, John wiley & Sons. Reproduced with permission from Bysted 
et al.48
parameters,   including levels of prothrombin fragment 
F1+2 (Figure 2B)48 and D dimer   (Figure 2C),48 activated 
partial thromboplastin time at 30 minutes postdose, and 
prothrombin time at 5 hours and 24 hours postdose, were 
also similar with the 2   formulations. Mean pharmacoki-
netic profiles were similar for the 2 formulations and are 
summarized in Table 2.48 A comparable hemostasis profile 
was demonstrated by consistent measures of coagulation 
and fibrinolysis. No adverse events were reported with 
the RT formulation in this study. In addition, no subjects 
developed treatment-related factor VIIa antibodies during 
the course of the trial.48
Conclusion
Despite remarkable advances in the treatment of hemophilia 
in recent decades, unmet clinical needs still exist, particu-
larly for patients whose condition is complicated by the 
development of high-titer inhibitors. Although long-term 
eradication of inhibitors by immune tolerance is desirable, 
the mainstay of treatment is the use of bypassing agents 
to treat acute bleeding episodes. The development of the 
rFVIIa-RT formulation allows immediate access through 
an improvement in portability, ease of storage, and the time 
needed for reconstitution, and should be a benefit to patients 
with hemophilia and inhibitors and their providers.
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